Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70489 ↗Kurz gefasst
Editorial in der Zeitschrift International Journal of Urology, online erschienen am 30.04.2026. Verfasst von Tsunenori Kondo. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
ORCID-Profile: Tsunenori Kondo
Zitieren
APA
Kondo, T. (2026). Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70489
Vancouver
Kondo T. Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70489
BibTeX
@article{Kondo2026,
author = {Kondo, Tsunenori},
title = {Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70489}
}
EUVIMED